Due to current HHS restructuring, the information provided on aspe.hhs.gov is not being updated currently. Please refer to hhs.gov for more information.
An official website of the United States government
Here’s how you know
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
This study, commissioned by ASPE, uses multiple data sources to 1) assess trends in pharmaceutical mergers and acquisitions (M&As) over the 2010-2023 period; 2) evaluate characteristics of drugs involved in M&As, and 3) examine the effects of M&As on the pharmaceutical supply chain.
The report, "Analysis of Drug Shortages, 2018-2023" provides additional information on the data, methods, and findings. Below are the key findings.KEY POINTS
Medical product shortages are an ongoing public health concern, with at least 140 products in shortage as of July 2024.We use the Household Pulse Survey to examine how many adults are affected by shortages of critical medical products in the United States.In fall 2023, shortages of medical products impacted about 38.8 million (18 percent) of individuals in the United Stat
Prescriptions dispensed for antipsychotics in nursing homes and assisted living facilities increased since the beginning of the pandemic, with 20.8 thousand dispensed in 2020 compared to 20.5 thousand in 2019. This represents a 1.5% increase in total prescriptions since the beginning of the pandemic despite lower resident census levels in long-term care facilities (LTCFs).
This report presents the findings from the Policy Analysis and Decision-Making Capacity project, funded by the Office of Science and Data Policy within the Office of the Assistant Secretary for Planning and Evaluation at the U.S. Department of Health and Human Services.
Prepared by: National Opinion Research Center (NORC) at the University of Chicago Prepared for:U.S. Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation
This paper examines the combined effects of drug plan risk the first year of Medicare part D implementation of the combination of reinsurance, risk-adjustment and risk-corridors